| Gene symbol | TP53 | Synonyms | BCC7, BMFS5, LFS1, P53, TRP53 | Type of gene | protein-coding | |
| Chromosome | 17 | Map location | 17p13.1 | dbXrefs | Entrez:7157 MIM:191170 HGNC:HGNC:11998 Ensembl:ENSG00000141510 AllianceGenome:HGNC:11998 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | tumor protein p53 | |||||
| GTO ID | GTC0060 |
| Trial ID | NCT00704938 |
| Disease | Melanoma | Kidney Cancer |
| Altered gene | P53 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | P53 TCR-T cells |
| Co-treatment | Filgrastim |
| HLA | HLA-A*02:01 |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | Phase II Study of Metastatic Cancer That Overexpresses p53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes and Dendritic Cell Vaccination |
| Year | 2008 |
| Country | United States |
| Company sponsor | National Institutes of Health Clinical Center (CC) |
| Other ID(s) | 080155|NCI-08-C-0155|NCI-P07215 |
| Cohort 1 | |||||||||||||||||
|
|||||||||||||||||